Cherry Cherry Therapeutics entered the industry of Biotherapeutics in 2005 and has grown to employ 1 to 4 people, generating an annual revenue of $1.000.000 to $2.499.999. The NAICS classifies this business under the code 4461100, which describes it as a Biotherapeutics. For further clarification, the SIC classifies this business under the code 5122 and described it as a Biotherapeutics. The business provides service to the BOTH market.
To acquire more information, please contact L Robinson, Principal by calling (619) 229-8958 during business hours. You can also write to the business’ Single Location at 4730 67th St, San Diego, California CA 92115. You can also visit the company’s website at . View this business’ social media profiles on Twitter or on Facebbok .
| Company: | Cherry Cherry Therapeutics |
| Representative: | L Robinson, Principal |
| Place of Business: | 4730 67th St, San Diego, CA 92115 |
| Contact Number: | (619) 229-8958 |
| Type of Service: | Biotherapeutics |
| SIC Number: | 5122 |
| NAICS Number: | 4461100 |
| Locality: | Single Location |
| Market Type: | B2B & B2C |
| Began: | 2005 |
| Income/Year: | $1.000.000 to $2.499.999 |
| Laborers: | 1 to 4 |
| Share This Company: |
Cherry Cherry Therapeutics is a company operating from San Diego, California providing professional Biotherapeutics and relevant BOTH variables. It was founded in 2005 and registered with the SIC code 5122 as Biotherapeutics, and with the NAICS code 4461100 as Biotherapeutics.
With a current employee count of 1 to 4, Cherry Cherry Therapeutics has gone to report making $1.000.000 to $2.499.999 per annum on its journey towards growth. This company invites you to contact its representative L Robinson, Principal at (619) 229-8958 for related queries, or to locate its Single Location using the coordinates 32.764072,-117.053206.
The Single Location can also be found at the street address 4730 67th St in San Diego, California 92115 and can be engaged online through the company website at , the company Twitter , and Facebook page .